Appointments

**Lawrence A. Aubin, Sr., Named Chairman of Lifespan Board of Directors**

PROVIDENCE – The Board of Directors of Lifespan has named **LAWRENCE A. AUBIN, SR.**, to lead the board. With his election, Aubin becomes the fifth chairman of the board in Lifespan’s 20-year history. He succeeds Scott Biren Laurans, who served a three-year term as chairman.

Aubin, who is the president and CEO of Seekonk, Massachusetts-based Aubin Corporation, is well known in the Lifespan community. Since the 1990s, he has been an active fundraiser for Hasbro Children’s Hospital, the pediatric division of Rhode Island Hospital, and has chaired or served on a number of Lifespan boards and committees, including as chairman of the Rhode Island Hospital Board of Trustees.

“Our board of directors could not have chosen a more qualified or committed individual to serve as chairman,” said Timothy J. Babineau, MD, president and chief executive officer of Lifespan. “I’ve had the pleasure of working with Larry since I first joined Rhode Island Hospital in 2008. Time and again, he has demonstrated his vast knowledge of our health care landscape, commitment to Lifespan and its partners, and profound dedication to the community we serve. He was integral in helping raise the philanthropic capital needed to create Hasbro Children’s Hospital, as well as the Child Protection Program that now bears his name.”

Aubin first joined the Rhode Island Hospital Board of Trustees in 1994, becoming its vice chairman in 2005 and then chairman in 2007. He became the vice chairman of the Lifespan Board of Directors in 2011. During his board tenure, Aubin has served on nearly all of the board’s committees. Through those efforts, he contributed to the completion of a number of significant building projects, such as the Bridge Building, the Andrew F. Anderson Emergency Center and the Comprehensive Cancer Center, which transformed the Rhode Island Hospital campus.

For nearly 20 years, Aubin has chaired or co-chaired the annual Hasbro Children’s Hospital Invitational Golf Tournament, which has raised more than $5 million. Aubin is also a member of the Regional Advisory Board of Citizens Bank, New England, and has served on the boards of Durfee-Attleboro Bank, South Shore Bank and Bank of Boston. He is also a member of the Providence College Business Advisory Council.

Aubin’s election to chairman coincides with other changes to the Lifespan Board of Directors. Joining the board are Jane Williams, PhD, RN, and Roger Begin. Completing their terms are Scott Biren Laurans, Michael G. Ehrlich, MD, Ellen Collins, David Brown, Jerrold Lavine and Jason Fowler.

**Lester P. Schindel Named CEO of CharterCARE Health Partners**

PROVIDENCE – **LESTER P. SCHINDEL** has been appointed Chief Executive Officer of CharterCARE Health Partners, a coordinated regional health care network that operates Roger Williams Medical Center, Our Lady of Fatima Hospital and a number of affiliated physician and health provider entities.

Schindel has spent the past five years as CEO and President of Steward Holy Family in Methuen, Mass., and Merrimack Valley Hospital in Haverhill, Mass., a 402-bed, two-campus hospital north of Boston that employs more than 2,100 health professionals, has a combined medical staff of 650 doctors and generated $280 million in net revenues last year. In addition, he has extensive experience in physician practice development and in the development of innovative collaborations and partnerships with allied health providers.

He will succeed Thomas Reardon who has served as Interim CEO and who will continue as President of Prospect East Holdings, Inc., a subsidiary of Prospect Medical Holdings, Inc. CharterCARE Health Partners is jointly owned by Prospect Medical Holdings, Inc. and CharterCARE Community Board.

“Our national search for a system CEO has led us to Lester, whose ability to manage a similar health system while developing effective strategic initiatives makes him a perfect fit for our organization,” Reardon said. “His experience will be critically important as CharterCARE continues to sustain, improve, and grow in Rhode Island.”

“I look forward to working with the CharterCARE physicians and staff and to guiding our system through a healthcare marketplace that, while challenging in many regards, also presents opportunities for organizations that deliver exceptional quality, improve access to services and manage costs,” stated Schindel.

Schindel will lead the further development of CharterCARE Health Partners. In particular, he will oversee the implementation of CharterCARE’s strategic plan, which envisions an integrated, multi-level network of healthcare providers to provide convenient access to high-quality care at lower costs. The complete network is expected to include urgent care centers, diagnostic services centers and additional physician groups.

Prior to leading Steward Holy Family and Merrimack Valley Hospital, Schindel was CEO of Essent Merrimack Valley Hospital, COO of MetroWest Medical Center in Natick, Mass and COO of Leonard Morse Hospital, also in Natick.

Schindel is a graduate of Rutgers University and received a master’s degree in health care administration from George Washington University. A Fellow of the American College of Healthcare Executives (FACHE), Schindel has delivered numerous addresses to a variety of national and regional health care organizations.
Doctor-patient confidentiality is no longer just a professional promise. It’s now a legal requirement.

Shred-it document destruction services can help you meet your compliance obligations with reliable, on-time service. We can help you prevent identity theft and security breaches, and safeguard your patients’ privacy so you can focus on other priorities.

“In healthcare, the security of patient information is critical. Shred-it gets it.”

Schedule your Free Security Assessment
Contact Shred-it today.
800 69.Shred
www.shredit.com/providence

Making sure it’s secure™

This offer will expire on December 31, 2013.
Recognition

URI College of Pharmacy Exceeds National Marks in Several Categories

99 percent pass rate on national board exam, student satisfaction measure among areas of excellence

KINGSTON – Students earning a six-year doctor of pharmacy degree from the University of Rhode Island achieved a 99 percent pass rate on the North American Pharmacist Licensure Examination, according to a 2014 report by the National Association of Boards of Pharmacy.

URI’s 2013 pass rate was four points higher than the national average and placed URI’s College of Pharmacy in a tie for first in New England with the University of Connecticut’s pharmacy school.

E. PAUL LARRAT, interim dean of URI’s College of Pharmacy, said the pass rate and a number of other benchmarks show that URI is not only keeping pace with pharmacy colleges across the country, but it is a national leader.

“During the last four years, our pass rate has been either 100 percent or 99 percent,” he said.

URI’s pharmacy employment rate at graduation of 97 percent makes it tops in New England. For every open seat in the college, URI has 10 qualified applications compared to the national average of 5.6.

And the College of Pharmacy’s on-time [six-year] graduation rate of 93 percent tops the national average by 4 points.

Appointment

Edward Donnelly, MD, Joins Newport Neurology

NEWPORT – Newport Hospital announced that neurologist EDWARD DONNELLY, MD, has joined Newport Neurology Services at Newport Hospital. Dr. Donnelly, who also serves as medical director of the hospital’s stroke program, began seeing patients on December 1.

Dr. Donnelly’s areas of specialty in neurology include epilepsy and seizures. As director of the Newport Hospital stroke program, he’ll provide both patient stroke care and community and physician education about stroke treatment and care.

Dr. Donnelly comes to Newport from Neurohealth, Inc. in Warwick. He is a graduate of Dartmouth Medical School and completed a fellowship in clinical neurophysiology at Rhode Island Hospital, where he also completed a residency in neurology. He is certified by the American Board of Psychiatry and Neurology.

Women & Infants Honors Ivonilde Burgess, RN, with DAISY Award

PROVIDENCE – Women & Infants Hospital recently honored IVONILDE BURGESS, RN, of Johnston, RI, a nurse in the hospital’s Infusion Center. The award is part of the DAISY Foundation’s program to recognize the above and beyond efforts performed by nurses every day. Ivonilde has been a nurse with Women & Infants for 14 years.

The not-for-profit DAISY Foundation is based in Glen Ellen, CA, and was established by family members in memory of J. Patrick Barnes. Patrick died at the age of 33 in late 1999 from complications of Idiopathic Thrombocytopenic Purpura [ITP], a little known but not uncommon autoimmune disease. The care Patrick and his family received from nurses while he was ill inspired this unique means of thanking nurses for making a profound difference in the lives of their patients and patient families.

Said Bonnie Barnes, president and co-founder of the DAISY foundation, “When Patrick was critically ill, our family experienced first-hand the remarkable skill and care nurses provide patients every day and night. Yet these unsung heroes are seldom recognized for the super-human work they do. The kind of work the nurses at Women & Infants Hospital are called on to do every day epitomizes the purpose of The DAISY Award.”

Ivonilde is the third recipient of the newly created DAISY award at Women & Infants and the second Infusion Center nurse to be honored.
Research

Bradley’s Marina Tolou-Shams, PhD, Awarded $2M Grant from National Institute on Drug Abuse

EAST PROVIDENCE – Marina Tolou-Shams, PhD, a psychologist from the Bradley Hasbro Children’s Research Center, has received a $2 million grant to study the efficacy of an intervention program for court-involved, non-incarcerated girls who use illicit substances.

The study, funded by the National Institute on Drug Abuse, will compare the gender-responsive program’s effect on reducing drug use and sexual risk behaviors relative to other community-based services that girls are typically referred to by the court.

“Compared to both non-offending girls and male offending counterparts, offending girls are at significantly greater risk for the development of substance use disorders, psychiatric symptoms and negative health outcomes, such as HIV/AIDS or other sexually transmitted infections,” said Dr. Tolou-Shams.

The study will enroll 200 Rhode Island Family Court-involved girls between the ages of 12 and 18 in either a gender-responsive drug use treatment program called VOICES, or into other community-based services deemed appropriate and necessary by the court. Dr. Tolou-Shams’ team will monitor the programs’ effects on the girls’ drug and alcohol use, HIV/STD risk behaviors, psychiatric symptoms and recidivism over both the short-term (three months post-program completion) and long-term (12 months post-completion).

The study will also identify the family and community factors that may impact the girls’ risk behaviors, such as parent/child communication or neighborhood environment. “Lack of engagement in treatment is a huge barrier to helping these young girls improve their health outcomes,” said Dr. Tolou-Shams.

She continued, “We have heard from facilitators across the country who already are implementing VOICES that girls continue to attend the program despite its frequency and intensity of 18 sessions, each 90 minutes long. If the VOICES intervention proves to be both efficacious in reducing juvenile justice girls’ drug use and co-occurring sexual risk behaviors and is perceived as more engaging by young girls, then we can feel more confident in continuing to disseminate this much-needed intervention to juvenile justice systems.”

Dr. Tolou-Shams, who is also director of the Rhode Island Family Court Mental Health Clinic, hopes that the findings from this study can immediately affect the way that practitioners help girls in the court system.

William M. Sikov, MD, Presents Benefits of Drug Additions on Women with Triple-Negative Breast Cancer

PROVIDENCE – William M. Sikov, MD, a breast cancer specialist and clinical research specialist at Women & Infants Hospital, presented research recently at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.

“We found that adding either carboplatin or bevacizumab to standard preoperative chemotherapy increased pathologic complete response rates for women with basal-like cancers – that is, it increased the proportion of women who had no residual cancer detected at surgery. At the same time, we found that while carboplatin had a similar effect in the smaller group of triple-negative patients with nonbasal-like cancers, adding bevacizumab actually decreased response rates for women with nonbasal-like cancers,” he said. He is associate chief of clinical research with the Program in Women’s Oncology at Women & Infants and associate professor of medicine at The Warren Alpert Medical School of Brown University.

Last year, Dr. Sikov and colleagues reported in a randomized, phase II clinical trial called CALGB/Alliance 40603 that adding either carboplatin or bevacizumab to standard preoperative chemotherapy increased pathologic complete response rates in 443 women with operable stage II or III triple-negative breast cancer. These latest results are based on analysis of tissue samples obtained before patients started treatment, correlated with findings at surgery after treatment. Pretreatment tumor samples from 360 of the patients showed that 314 were basal-like and 46 nonbasal-like.

“We have also looked at expression of variety of gene signatures in the pretreatment tissue samples to determine if they benefit from the addition of bevacizumab or carboplatin,” Dr. Sikov said. “We found that gene signatures characteristic of high proliferation rates and low estrogen-receptor signaling, which are both considered characteristics of more aggressive disease, are associated with higher rates of response rates overall and increased benefit from adding bevacizumab.”

Other studies using tissue and blood samples obtained from the patients treated on this study – funded by the National Cancer Institute, Roche-Genentech, and the Breast Cancer Research Foundation – are ongoing.
Obituary

DR. ANTHONY T. CARRELLAS, 91, of Newport, died Friday, December 19, 2014 at Forest Farm Health Care Center Middletown, RI with his family by his side. He was the husband of the late Mary Louise (Stanton) Carrellas.

He graduated from the College of The Holy Cross in 1945 in three years. At the time, all male college students were required to take part in a new program established by the government. Termed “Accelerated Schooling,” it sped up one's college education to facilitate the draft. Dr. Carrellas attended New York Medical College, Flower and Fifth Avenue Hospitals from 1945–1949. He completed a two-year rotating internship in Washington, D.C., from 1949–1951.

Subsequently he served in the United States Army Medical Corps for nearly two years during the Korean War. Dr. Carrellas then completed a two-year residency in pediatrics at the District of Columbia General Hospital in Washington, D.C. In 1954, while at a hospital Christmas party, he met his future wife, pediatric nurse, Mary Lou Stanton. They were married October 1, 1955 in Johnstown, PA, and returned to Newport, where Dr. Carrellas practiced pediatrics until 1992.

Affectionately known as “Dr. Bowtie,” he served young patients from all over Aquidneck Island for 37 years. Dr. Carrellas was renowned for the numerous house calls he made throughout his career. He served as the medical staff president for Newport Hospital from 1972–1974.

Dr. Carrellas served as the Middletown school physician for almost twenty years. He was a board member of The Boys and Girls Club of Newport County as well as The Newport Federal Savings Bank for many years. Dr. Carrellas was an active supporter of a variety of organizations within his community. He was particularly fond of volunteering for Meals on Wheels.

He is survived by his children, Dr. Robert A. Carrellas and his wife Mimi of Middletown, David Carrellas of Newport, Ann Carrellas of Ann Arbor, MI; Dr. Joan Carrellas and her husband Vincent Chmielarczyk of Santa Fe, NM; and Patricia G. Carrellas and her husband Stephan Boneu of Portsmouth, and his many grandchildren.

Donations in his memory may be made to the Newport Hospital Foundation, 11 Friendship Street, Newport RI 02840 or to Meals on Wheels, 70 Bath Street, Providence RI 02903.